Compare TTC & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTC | MDGL |
|---|---|---|
| Founded | 1914 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Tools/Hardware | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 10.0B |
| IPO Year | 1994 | 2005 |
| Metric | TTC | MDGL |
|---|---|---|
| Price | $94.15 | $520.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $104.00 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 976.5K | 294.7K |
| Earning Date | 03-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $2,618,650,000.00 | $180,133,000.00 |
| Revenue This Year | $6.11 | $58.28 |
| Revenue Next Year | $4.45 | $46.80 |
| P/E Ratio | $136.06 | ★ N/A |
| Revenue Growth | ★ 4.53 | N/A |
| 52 Week Low | $62.34 | $265.00 |
| 52 Week High | $105.19 | $615.00 |
| Indicator | TTC | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 42.83 | 72.06 |
| Support Level | $76.60 | $411.87 |
| Resistance Level | $102.32 | $610.00 |
| Average True Range (ATR) | 2.41 | 23.48 |
| MACD | -0.47 | 8.44 |
| Stochastic Oscillator | 22.78 | 65.23 |
The Toro Co designs, manufactures, markets, and sells professional turf maintenance equipment and services; turf and agricultural irrigation systems; landscaping equipment and lighting products; snow and ice management equipment; construction equipment; and residential yard and snow thrower products. The company operates through Professional and Residential segments, with the Professional segment serving commercial, agricultural, and construction customers and generating the majority of revenue, while the Residential segment focuses on homeowners. Its products are sold through distributors, dealers, retailers, rental centers, and direct channels, with the United States as its primary revenue-generating market.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.